tirzepatide and svt Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice Tirzepatide (Zepbound)

In the STEP 2 trial, patients with type 2 diabetes who took semaglutide 2.4 mg lost nearly 9.6% of their body weight over 68 weeks, compared with approximately 3% on placebo

This approach has shown better outcomes for weight maintenance in real-world settings compared to sudden discontinuation

Avoid high-fat and high-acid foods that trigger reflux independently of semaglutide

When a 62-year-old woman drinks two shots of whiskey every night for 40 years to deal with life, I expect her to continue

N Engl J Med 385(10):896907 Gofron KK, Wasilewski A, Magorzewicz S (2025) Effects of GLP-1 analogues and agonists on the gut microbiota: a systematic review